Phase III Multicenter Randomized trial of CPX-351 (Cytarabine: Daunorubicin) Liposome injections vs Cytarabine and Daunorubicin in Patients 60-75 years of age with untreated high risk (secondary) AML
|Effective start/end date||10/30/12 → 3/30/20|
- CELATOR PHARMACEUTICALS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.